[ad_1]
Now a scientifically revised study of Astra Zeneca’s covid-19 vaccine is presented. The results, reported in The Lancet, refer to the AZD1222 vaccine, which the company developed in collaboration with researchers at the University of Oxford in the UK. These are the so-called intermediate results, that is, half-time results.
The study shows, like the company The previous press release announced that the protective effect of the symptomatic covid-19 vaccine is on average 70 percent, but that the protective effect varies between 62 and 90 percent, depending on the two different doses administered during clinical trials. So far, no hospital admissions or more severe cases of covid-19 have been observed in the vaccinated groups.
The vaccine’s safety profile is “acceptable,” the researchers write. This despite the fact that three cases of serious adverse events occurred among the more than 23,700 participants.
One of the events occurred among those who received placebo, while another occurred among those who received vaccines. This was a case of transverse myelitis, that is, an unusual inflammation of the spinal cord, something that the researchers believe may have to do with the vaccine.
It is not yet clear whether the third case was vaccinated or not, due to the design of the studies with groups of participants in which it is not yet known whether they have been vaccinated or not. All people have recovered or are about to recover, according to the researchers.
“Our results suggest that the efficacy of the vaccine exceeds the requirements of health authorities and has the potential to affect public health,” research leader Andrew Pollard, a professor at the University of Oxford, told the journal.
